Q3 EPS Forecast for Sensei Biotherapeutics Raised by Analyst

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Sensei Biotherapeutics in a research note issued to investors on Wednesday, August 5th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.58) per share for the quarter, up from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Sensei Biotherapeutics’ current full-year earnings is ($15.23) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($13.54) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.63) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.75) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($2.54) EPS.

Several other equities research analysts have also recently weighed in on FTH. Citigroup began coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Finally, Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.90.

Sensei Biotherapeutics Price Performance

FTH opened at $24.48 on Friday. Sensei Biotherapeutics has a 52 week low of $7.20 and a 52 week high of $37.90. The company has a market capitalization of $32.85 million, a PE ratio of -0.17 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter.

Insiders Place Their Bets

In other news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the first quarter worth about $4,188,000. Vivo Capital LLC bought a new stake in shares of Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. Bank of America Corp DE raised its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across every reported period. The firm reduced its expected losses for Q3 2026 to $0.58 per share from $0.69, FY2026 to $13.54 from $16.61, and FY2027 to $2.68 from $3.72. It also improved estimates for FY2028, FY2029 and FY2030, suggesting the analyst expects Sensei Biotherapeutics’ financial performance to improve more quickly than previously projected.
• Positive Sentiment: The revisions also covered 2027 quarterly results, with projected losses narrowed to $0.61 per share in Q1, $0.63 in Q2, $0.66 in Q3 and $0.75 in Q4. Although the company remains unprofitable, the direction of the revisions is favorable and may strengthen investor confidence in its longer-term outlook.
• Neutral Sentiment: JonesTrading began coverage of Sensei Biotherapeutics. The article does not disclose a rating, price target or detailed investment thesis, so the immediate effect of the new coverage is uncertain. JonesTrading Begins Coverage on Sensei Biotherapeutics
• Negative Sentiment: Despite the improved forecasts, HC Wainwright still expects substantial losses, while the broader current-year consensus calls for a $15.23-per-share loss. Sensei Biotherapeutics’ latest reported quarterly EPS was also negative at $131.45, highlighting the company’s continuing profitability and execution risks.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.